BDBM802077 methyl (S)-3-((2S,4R)-1-((S)- 3-cyclopropyl-7,7-dimethyl- 7,8-dihydro-4H,6H-[1,2,3] triazolo[5,1-c][1,4]oxazepine- 8-carbonyl)-4-hydroxypyrrol- idine-2-carboxamido)-3-(4- (2,4-dimethyloxazol-5-yl)- phenyl)propanoate::US20260108613, Compound A26

SMILES COC(=O)C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H]1n2nnc(C3CC3)c2COCC1(C)C)c1ccc(-c2oc(C)nc2C)cc1

InChI Key

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 802077   

Targetvon Hippel-Lindau disease tumor suppressor(Human)
University of Michigan

US Patent
LigandChemical structure of BindingDB Monomer ID 802077BDBM802077(methyl (S)-3-((2S,4R)-1-((S)- 3-cyclopropyl-7,7-di...)
Affinity DataIC50: 11.1nMAssay Description:JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
9/2/2026
Entry Details
US Patent